Breakthroughs that break through pain and addiction

Channel Pharmaceutical Corporation is developing innovative non-addictive, drugs to treat
chronic neuropathic and acute and chronic eye pain.

An Urgent Need

Idiopathic Small Fiber Neuropathy (iSFN) and Erythromelalgia (EM) our first two indication, both eligible for orphan drug designation, providing both substantial market potential and faster approval. There are currently no approved drugs for either indication.

A Non-Opiod Alternative

Our patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post surgical, and chemotherapy induced.